SOX Sequential S-1 in Advanced Biliary Tract Carcinoma（BTC）and Pancreatic Cancer
This is an exploratory, single-armed, open label study on the efficacy and safety of sequential S-1 therapy after SOX in unresectable metastatic or locally advanced biliary system or periampullary cancer or pancreatic cancer patients. The primary endpoint is Objective response rate and secondary endpoint is progression free survival , overall survival ,1 year survival rate and safety.
Biliary Tract Cancer|Periampullary Adenocarcinoma|Pancreatic Cancer
DRUG: SOX sequential S-1
Objective response rate for SOX sequential S-1, The primary endpoint is objective response rate,which equals CR+PR., 1 years
Overall Survival, OS means that from the first dose of treatment drug to death or lost, the follow-up visit will be performed every 3 months till death or lost, 2 years|progression free survival, PFS means that from the first dose of treatment drug to disease progression or death or lost, the follow-up visit will be performed every 6 weeks till progression or death or lost, 1 year|1 year survival rate, the follow-up visit of survival will be performed every 3 months till 1 year, 1 year|Number of Participants with Adverse Events as a Measure of Safety and Tolerability, participants will be followed for the duration of hospital stay, an expected average of 3 weeks, 2 years
This is an exploratory, single-armed, open label study on the efficacy and safety of sequential S-1 therapy after SOX in unresectable metastatic or locally advanced biliary system or periampullary cancer or pancreatic cancer patients. The primary endpoint is Objective response rate and secondary endpoint is progression free survival , overall survival ,1 year survival rate and safety.